Pluri
Haifa, Israel· Est.
Pluri leverages a proprietary 3D cell‑expansion platform to deliver scalable, off‑the‑shelf placental cell therapies and cultivated food solutions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Pluri leverages a proprietary 3D cell‑expansion platform to deliver scalable, off‑the‑shelf placental cell therapies and cultivated food solutions.
Regenerative MedicineOrthopedicsVascular Medicine
Technology Platform
Patented 3D cell‑expansion bioreactor that scales single cells to billions, enabling automated, cost‑effective production of high‑quality placental‑derived mesenchymal‑like cells (PLX).
Opportunities
Commercialization of PLX‑PAD across orthopedics and vascular indications, plus expansion into cultivated food markets, could drive multi‑billion‑dollar revenue streams.
Risk Factors
Regulatory approval uncertainties, scaling manufacturing to commercial volumes, and competition from larger cell‑therapy platforms pose significant risks.
Competitive Landscape
Pluri competes with established cell‑expansion providers such as Lonza, Thermo Fisher, and emerging biotech firms; its differentiation lies in its patented 3D bioreactor and placenta‑derived PLX cell line.